Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Real Time Quote from BATS)

$28.36 USD

28.36
796,545

-0.75 (-2.58%)

Updated Sep 19, 2025 03:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

by Zacks Equity Research

Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

    Zacks Equity Research

    The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical

      Zacks Equity Research

      Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

      by Zacks Equity Research

      Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

        Zacks Equity Research

        Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate

        by Zacks Equity Research

        Ultragenyx (RARE) forwards a BLA to the FDA for burosumab with a view to treat patients with X-linked hypophosphatemia (XLH). The decision on acceptance will be known within a couple of months.

          Zacks Equity Research

          Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data

          by Zacks Equity Research

          Ultragenyx (RARE) plans to discontinue further clinical development of Ace-ER after posting discouraging data from a phase III study that evaluated the candidate on patients with GNE Myopathy.

            Zacks Equity Research

            Ultragenyx Receives Priority Review for rhGUS from FDA

            by Zacks Equity Research

            The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

              Zacks Equity Research

              What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

              by Zacks Equity Research

              Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.

                Zacks Equity Research

                Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store?

                by Zacks Equity Research

                Celldex Therapeutics, Inc. (CLDX) is expected to report first-quarter 2017 results on May 4. Celldex's performance has been encouraging with a three-quarter average positive surprise of 8.06%.

                  Zacks Equity Research

                  Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?

                  by Zacks Equity Research

                  ImmunoGen, Inc. (IMGN) is scheduled to report first-quarter 2017 results on May 5, before the opening bell.

                    Zacks Equity Research

                    What's in the Cards for ACADIA (ACAD) this Earnings Season?

                    by Zacks Equity Research

                    ACADIA Pharmaceuticals Inc. (ACAD) is expected to report first-quarter 2017 results on May 4.

                      Zacks Equity Research

                      What's in Store for Zoetis (ZTS) Stock This Earnings Season?

                      by Zacks Equity Research

                      Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.

                        Zacks Equity Research

                        What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?

                        by Zacks Equity Research

                        Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.

                          Zacks Equity Research

                          What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?

                          by Zacks Equity Research

                          Juno Therapeutics Inc. (JUNO) is scheduled to report first-quarter 2017 results on May 4, after the market closes.

                            Zacks Equity Research

                            What to Expect from Keryx (KERX) Stock This Earnings Season?

                            by Zacks Equity Research

                            Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.

                              Zacks Equity Research

                              BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?

                              by Zacks Equity Research

                              We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                                Zacks Equity Research

                                What's in Store for Nivalis (NVLS) this Earnings Season?

                                by Zacks Equity Research

                                Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.

                                  Zacks Equity Research

                                  What's in Store for Vertex (VRTX) this Earnings Season?

                                  by Zacks Equity Research

                                  Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.

                                    Zacks Equity Research

                                    What's in Store for AbbVie (ABBV) this Earnings Season?

                                    by Zacks Equity Research

                                    AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.

                                      Zacks Equity Research

                                      Company News for April 20, 2017

                                      by Zacks Equity Research

                                      Companies in the News are: LRCX,FB,RARE,ABT

                                        Zacks Equity Research

                                        Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

                                        by Zacks Equity Research

                                        Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH).

                                          Zacks Equity Research

                                          Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

                                          by Zacks Equity Research

                                          Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate burosumab (KRN23).

                                            Zacks Equity Research

                                            Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study

                                            by Zacks Equity Research

                                            Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.

                                              Zacks Equity Research

                                              Ultragenyx's (RARE) KRN23 Accepted for Review in the EU

                                              by Zacks Equity Research

                                              Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.

                                                Zacks Equity Research

                                                Ultragenyx (RARE) Reports Positive Phase II Study on UX007

                                                by Zacks Equity Research

                                                Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).